Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02845479
Other study ID # 20150449-01H
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date December 7, 2018
Est. completion date December 7, 2020

Study information

Verified date March 2024
Source The Canadian College of Naturopathic Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Stage I of the Thoracic-POISE study will pilot-test a broad-based, multi-agent integrative care intervention delivered by naturopathic doctors in conjunction with standard surgical and oncologic care of people with thoracic cancer.


Description:

Despite enormous advances in thoracic surgery and oncology, two critical issues concern patients undergoing curative-intent surgery for lung, gastric and esophageal cancer: first, a majority (~60%) of patients experience minor and major adverse events occurring during and in the days following surgery; second, patients worry about the significant risk of cancer recurrence and mortality months to years after surgery. These issues, combined with side effects of chemotherapy and radiation, have detrimental effects on health-related quality of life (HRQoL). On a deeper level, there is the problem of an ongoing failure to integrate and evaluate the best of what complementary medicine has to offer surgical oncology care. The Thoracic-POISE Project has the overarching goal of improving care for thoracic cancer patients by impacting HRQoL, reducing surgical adverse events, prolonging overall survival and pioneering integrative care delivery. This multi-stage project aims to design, pilot-test and evaluate a broad-based, multi-agent, evidence-based integrative care program to be delivered by naturopathic doctors (ND) in conjunction with standard surgical and oncologic care. It is hypothesized that this integrative care program will improve HRQoL as well as reduce surgical adverse events and improve cancer survival. Stage I of the project will pilot-test the intervention and outcomes collection in a single-arm, feasibility study.


Recruitment information / eligibility

Status Completed
Enrollment 22
Est. completion date December 7, 2020
Est. primary completion date December 1, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adults eligible and scheduled for major thoracic surgery for lung, gastric or esophageal cancer - Candidate for complete resection - Willingness to include an integrative component to their care - Availability for follow-up visits over the course of one year - Willingness to be interviewed regarding their experience of care - Ability to answer self- and interviewer- administered questions in English or French - Understand and sign a written informed consent form in English or French Exclusion Criteria: - Small cell, carcinoid, or gastrointestinal stromal (GIST) tumours - History of cancer in the last 3 years - Already seeing a ND or involved in an integrative program of care in the last 3 months that includes complementary medicine

Study Design


Intervention

Other:
Integrative Care
Standardized supplemental/natural health product, physical, nutritional and mental/emotional recommendations based on the phases of standard care (neo-adjuvant, perioperative, adjuvant and long-term maintenance).

Locations

Country Name City State
Canada Ottawa General Hospital Ottawa Ontario
Canada Ottawa Integrative Cancer Centre Ottawa Ontario

Sponsors (3)

Lead Sponsor Collaborator
The Canadian College of Naturopathic Medicine Lotte & John Hecht Memorial Foundation, Ottawa Hospital Research Institute

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Adverse events Collection of adverse events related to surgery, adjuvant therapy, and the interventions Enrollment - 1 year post surgery
Other Health Related Quality of Life Functional Assessment of Cancer Therapy-General Score Enrollment - 1 year post surgery
Other Cancer-related symptoms Edmonton Symptom Assessment Scale Enrollment - 1 year post surgery
Other Anxiety and Depression Hospital Anxiety and Depression Scale Enrollment - 1 year post surgery
Other Fatigue Multidimensional Fatigue Inventory Enrollment - 1 year post surgery
Other Functional exercise capacity 6 minute walk test Enrollment - 1 year post surgery
Other Inflammation: Multi-analyte cytokine array. Plasma concentrations of a panel of cytokines (IL2, IL10, TGF-beta, TNF-alpha, IFN-alpha, and IFN-gamma) will be measured in blood samples collected 4 weeks before surgery, 2-3 days before surgery, on post-operative day (POD) 1, POD 5 (+/-2), 3-4 weeks, 6 months and 1 year post-surgery Enrollment - 1 year post surgery
Other Natural kill cell activation NK cell activity will be measured by NKVue™ in blood samples collected 4 weeks before surgery, 2-3 days before surgery, on post-operative day (POD) 1, POD 5 (+/-2), 3-4 weeks, 6 months and 1 year post-surgery Enrollment - 1 year post surgery
Primary Feasibility of study protocol Percentage of participants who complete all assessments and integrative care appointments Enrollment - 1 year post surgery
Secondary Compliance: supplemental intervention Count of missed doses assessed by patient diary. Enrollment - 1 year post surgery
Secondary Compliance: nutritional intervention Mediterranean diet score calculated by food frequency questionnaire administered at enrollment and 1 year post surgery Enrollment - 1 year post surgery
Secondary Compliance: physical intervention Extent of adherence to physical activity recommendations assessed using a patient diary. Enrollment - 1 year post surgery
Secondary Compliance: mental/emotional domain Number of days audio-recordings were used assessed by patient diary. Enrollment - 1 year post surgery
Secondary Communication between practitioners Number of communications (phone, consult note, etc.) between integrative and standard care practitioners per participant Enrollment - 1 year post surgery
Secondary Qualitative experience of care and study protocol Semi-structured interviews with thematic analysis Enrollment - 1 year post surgery
Secondary Feasibility of recruitment Percentage of participants recruited out of potentially eligible patients invited. Enrollment
See also
  Status Clinical Trial Phase
Recruiting NCT03357094 - Pulmonary Ventilation/Perfusion Imaging for the Prediction of Postoperative Residual Pulmonary Function N/A
Recruiting NCT05543954 - 68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer Patients Early Phase 1
Completed NCT01114958 - Pilot Study of Intra-Arterial Cisplatin With IV Thiosulfate in Patients With Lung Cancer or Lung Metastases Phase 1
Recruiting NCT06004440 - Real World Registry for Use of the Ion Endoluminal System
Not yet recruiting NCT02907606 - Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study N/A
Completed NCT02926768 - Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors Phase 1
Active, not recruiting NCT02514512 - Lung Cancer Radiotherapy Using Realtime Dynamic Multileaf Collimator (MLC) Adaptation And Radiofrequency Tracking N/A
Completed NCT02531737 - Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With Lung Cancer Phase 2
Completed NCT02334007 - Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery Phase 1/Phase 2
Active, not recruiting NCT02284633 - Blood Sample Monitoring of Patients With EGFR Mutated Lung Cancer
Completed NCT02106143 - RejuvenAir™ System Lobectomy Safety and Histology Study N/A
Completed NCT01933789 - Improving Communication About Serious Illness N/A
Enrolling by invitation NCT01687647 - Sputum Cytometry Analysis in Lung Cancer Screening After Professional Asbestos Exposure Phase 3
Completed NCT00243685 - Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis Phase 2/Phase 3
Terminated NCT00356525 - Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor Phase 2
Completed NCT00385177 - Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors Phase 1
Completed NCT00351962 - Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable NSCLC or Metastatic Lung Tumours N/A
Completed NCT00129844 - Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer Phase 2
Withdrawn NCT00090701 - A Phase 2, Open-Label, Multicenter Study of the GARFT Inhibitor in Patients With Metastatic Non-Small Cell Lung Cancer Phase 2
Recruiting NCT01789229 - Establishment of a Tumor Bank for Tissue Samples